This is what Andrew Chapman has to say in the latest Merchant...

This is what Andrew Chapman has to say in the latest Merchant Funds newsletter

Healthcare & Biotechnology

I expect that the current Biotech boom to last into late 2014, early 2015. With emerging confidence across the globe and investment dollars chasing alternatives to the Mining sector plus recent successes from a market perspective (ISN, OSL and RGS – all up over 100% recently), will ensure that the sector continues to be in focus into the New Year.

From a MOF perspective Calzada is where our focus lies and with the recent announcement of Dr Roger Aston assuming the vacated Chairman’s role (David Franklyn not standing for re-election), I feel that Calzada will be entering a period of change and consolidation headed by arguably, one of the best Biotech brains in the country.


http://www.merchantgroup.com.au/news/merchant-opportunities-fund-newsletter-october-2013.html

I guess he has an exit strategy at a price well north of where we are atm. That is comforting.